A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.

Jennifer Susan LeesStephen J H DobbinBenjamin M P ElyanDavid F GilmourLaurie A TomlinsonNinian N LangPatrick B Mark

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)

In trials of intravitreal VEGFi, we did not identify an increased risk of cardiorenal outcomes, though these outcomes were reported in only a minority of cases. There was an increased risk of death in VEGFi-treated participants with diabetic eye disease. Additional scrutiny of post-licensing observational data may improve recognition of safety concerns in VEGFi-treated patients.

Keyphrases

vascular endothelial growth factor
newly diagnosed
end stage renal disease
ejection fraction
diabetic retinopathy
prognostic factors
age related macular degeneration
cross sectional
electronic health record
weight loss
deep learning
optical coherence tomography